Results 51 to 60 of about 21,820 (216)

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

Microbiology Spectrum, 2022
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi, Renru Han, Yan Guo, Yang Yang, Shi Wu, Li Ding, Rong Zhang, Dandan Yin, Fupin Hu   +8 more
doaj   +1 more source

Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract There are currently no oral treatment options for infections caused by extended spectrum β‑lactamase‐producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections ...
Siddhee A. Sahasrabudhe, Satoshi Shoji, Abhijeet S. Jakate, Bisrat K. Abraham, Sima S. Toussi, Benjamin J. Maligalig, Amanda S. Darekar, Sakambari Tripathy, Constantino Kantaridis, Josue K. Mfopou, Oxana Selivanova, Arthur Bergman, Negar Niki Alami, Ravi Shankar P. Singh   +13 more
wiley   +1 more source

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU

, 2023
Jiaxin Yu,1,2 Wei Zuo,1,2 Hongwei Fan,1,3 Jiayu Wu,1,2 Luyao Qiao,1,2,4 Benyu Yang,1,2,5 Wenxi Li,1,2,5 Yang Yang,1,2,* Bo Zhang1,2,* 1Department of Pharmacy, Peking Union Medical College Hospital, Beijing, People’s Republic of China; 2State Key ...
Zuo W, Li W, Wu J, Fan H, Yang Y, Yang B, Yu J, Zhang B, Qiao L   +8 more
core  

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate [PDF]

, 2015
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella ...
Humphries, Romney M, Yang, Shangxin, Hemarajata, Peera, Gregson, Aric, Hindler, Janet A, Ward, Kevin W, Miller, Shelley A   +6 more
core   +1 more source

In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

Journal of Global Antimicrobial Resistance, 2020
Objectives: The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood ...
Chiara Papalini, Samuele Sabbatini, Claudia Monari, Antonella Mencacci, Daniela Francisci, Stefano Perito, Maria Bruna Pasticci   +6 more
doaj   +1 more source

Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
Development and application of PBPK modeling integrating CRRT as a virtual organ to characterize antimicrobial pharmacokinetics and optimize dosing in septic patients. ABSTRACT Continuous renal replacement therapy (CRRT) extracorporeal drug removal, sepsis‐related pathophysiological alterations, and reduced pathogen susceptibility to antimicrobials can
Yuanming Xing, Yijing Zhang, Chuqi Bai, Yulan Qiu, Chuhui Wang, Lei Chen, Taotao Wang, Jiaojiao Chen   +7 more
wiley   +1 more source

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Frederik Boetius Hertz, Frank Hansen, Kolpen, Mette, Løbner-Olesen, Anders, Niels Frimodt-Møller, Godefroid Charbon, Frimodt-Møller, Niels, Karoline Knudsen List, Stine Radmer, Kasper Nørskov Kragh, List, Karoline Knudsen, Charbon, Godefroid, Radmer, Stine, Hertz, Frederik Boetius, Kragh, Kasper Nørskov, Hansen, Frank, Mette Kolpen, Anders Løbner-Olesen   +17 more
core   +1 more source

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

mSphere, 2019
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich, Vidar Sørum, Ane Molden Thomassen, Pål Jarle Johnsen, Hanna-Kirsti S. Leiros, Ørjan Samuelsen   +5 more
doaj   +1 more source